34 results about "Withaferin A" patented technology

The present invention relates to an improved process of analytical and quantitative isolation of withaferin-A from Withania somnifera (Sanskrit: Ashwagandha, English: winter cherry) and other plants and products therefrom, said method comprising steps of selecting most appropriate extraction medium composition, with extraction solvent system consisting of a defined admixture of water and alcohol in a range of proportion of alcohol within a narrow range of (methanol, ethanol etc.) (preferably 60% alcohol and 40% water) for the dry plant material and from 60% to 80% alcohol in the alcohol-water mixture for fresh plant material, the invented extractant composition leading to better / improved yields and accurate quantitative estimations of withaferin A existent in planta or in materia, selecting effective state of the tissue particularly use of the fresh materials improving yields, providing logistic benefits of isolations and diagnosis, and according several other advantages including technological, economic, preventing contaminations etc., the said method being valuable and advantageous for standardization of botanicals, metabolomic characterization of plants particularly chemotypes, analyzing metabolic transitions under physiological, genetical, environmental and biotic perturbations.

Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from Withania somnifera to effectively block NF-kB activation in beta cells, minimize cytokine-induced cell death and improve survival of transplanted islets. The method of the present invention involves identifying a subject having islet cells in need of treatment; and providing a effective amount of a Withaferin A composition disposed in a pharmaceutically acceptable carrier in an amount sufficient to reduce the inflammation after cytokine exposure without affecting the viability and potency of the islet cell population.

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

A method for prevention and / or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV / TV %) by 3 folds as compared to free Withaferin A (WFA).

The invention provides a composition containing withaferin A, and relates to the technical field of medicines. The composition comprises topiramate and the withaferin A in a mass ratio of (1-25)*10<3>:1. Through the combined application of the topiramate and the withaferin A, the using amount of the topiramate and the withaferin A can be reduced, the side effects of the topiramate and the withaferin A can be obviously reduced, and the effects of reducing the body weight, improving the insulin sensitivity and optimizing the lipid metabolism more significantly can be achieved. The composition can still achieve the effects of significantly reducing the body weight, improving the insulin sensitivity and optimizing the lipid metabolism when the dosage is halved.

The invention discloses application of Withaferin A in preparing a drug for treating a fundus ischemic disease. Experiments show that the Withaferin A can inhibit the fundus ischemic disease from theperspective of pathogenesis through two mechanisms that 1, oxidative stress cell necrosis and apoptosis caused by ischemia are significantly reduced; 2, targeted inhibition of a vascular endothelial growth factor and a signaling pathway of a receptor (VEGF-VEGFR2) of the vascular endothelial growth factor is achieved, and the pathological microvascular hemorrhage leakage, abnormal blood vessel growth and other symptoms are ameliorated. The Withaferin A significantly relieves the symptoms of the fundus ischemic disease and inhibits the generation and development of the disease through the dualeffects of the two mechanisms. The Withaferin A as a small molecule targeting compound has a stable and safe chemical structure and can penetrate through a blood-eye barrier, therefore the WithaferinA has a broad application prospect in the fundus ischemic disease.

The invention provides a medicinal composition containing withaferin A and an application thereof, which belong to the technical fields of medical science and biology. The medicinal composition comprises withaferin A and quercetin, the mass ratio of the withaferin A to quercetin is 1: (1 to 1500). In the present invention, the medicinal composition is possible to prevent and treat neurodegenerative diseases, protects neurons, improves the distribution and morphology of tyrosine hydroxylase-positive neurons in the mass ratio of withaferin A to quercetin, treats neuroinflammation, not only significantly reduces the usage dosage, but also achieves better results than single usage.